SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the June 2023 quarter moved down to Rs. 874.68 millions as compared to Rs. 1094.95 millions during the year-ago period.The Net Loss for the quarter ended June 2023 is Rs. -95.35 millions as compared to Net Profit of Rs. 30.05 millions of corresponding quarter ended June 2022Operating profit Margin for the quarter ended June 2023 slipped to -34.54% as compared to 103.84% of corresponding quarter ended June 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 874.68 1094.95 -20.12 874.68 1094.95 -20.12 3722.53 4510.68 -17.47
Other Income 0.20 0.07 185.71 0.20 0.07 185.71 4.36 0.89 389.89
PBIDT -34.54 103.84 -133.26 -34.54 103.84 -133.26 259.54 491.45 -47.19
Interest 34.12 35.45 -3.75 34.12 35.45 -3.75 127.51 111.62 14.24
PBDT -68.66 68.39 -200.39 -68.66 68.39 -200.39 132.03 379.83 -65.24
Depreciation 34.19 26.00 31.50 34.19 26.00 31.50 109.89 102.49 7.22
PBT -102.85 42.39 -342.63 -102.85 42.39 -342.63 22.14 277.34 -92.02
TAX -7.50 12.34 -160.78 -7.50 12.34 -160.78 9.44 80.76 -88.31
Deferred Tax -7.50 -0.96 681.25 -7.50 -0.96 681.25 9.70 -7.32 -232.51
PAT -95.35 30.05 -417.30 -95.35 30.05 -417.30 12.70 196.58 -93.54
Equity 158.28 158.28 0.00 158.28 158.28 0.00 158.28 158.28 0.00
PBIDTM(%) -3.95 9.48 -141.64 -3.95 9.48 -141.64 6.97 10.90 -36.01

Mangalam Drugs&Org. Share Price

29.75 0.02 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×